PT1083899E - Derivados de 1-desoxi-galactonojirimicina e respectiva utilização no tratamento de doenças de acumulação lisossomal, por intensificação da alfa-galactosidase a lisossomal - Google Patents
Derivados de 1-desoxi-galactonojirimicina e respectiva utilização no tratamento de doenças de acumulação lisossomal, por intensificação da alfa-galactosidase a lisossomal Download PDFInfo
- Publication number
- PT1083899E PT1083899E PT99925611T PT99925611T PT1083899E PT 1083899 E PT1083899 E PT 1083899E PT 99925611 T PT99925611 T PT 99925611T PT 99925611 T PT99925611 T PT 99925611T PT 1083899 E PT1083899 E PT 1083899E
- Authority
- PT
- Portugal
- Prior art keywords
- lysosomal
- galactonojirimycin
- deoxy
- galactosidase
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/087,804 US6274597B1 (en) | 1998-06-01 | 1998-06-01 | Method of enhancing lysosomal α-Galactosidase A |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1083899E true PT1083899E (pt) | 2009-12-18 |
Family
ID=22207362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT90117615T PT2143420E (pt) | 1998-06-01 | 1999-05-28 | Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry |
PT99925611T PT1083899E (pt) | 1998-06-01 | 1999-05-28 | Derivados de 1-desoxi-galactonojirimicina e respectiva utilização no tratamento de doenças de acumulação lisossomal, por intensificação da alfa-galactosidase a lisossomal |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT90117615T PT2143420E (pt) | 1998-06-01 | 1999-05-28 | Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry |
Country Status (12)
Country | Link |
---|---|
US (16) | US6274597B1 (pt) |
EP (2) | EP1083899B1 (pt) |
JP (2) | JP4602548B2 (pt) |
AT (1) | ATE442851T1 (pt) |
AU (1) | AU4186199A (pt) |
CA (1) | CA2333965C (pt) |
CY (2) | CY1112845T1 (pt) |
DE (1) | DE69941429D1 (pt) |
DK (2) | DK1083899T3 (pt) |
ES (2) | ES2333561T3 (pt) |
PT (2) | PT2143420E (pt) |
WO (1) | WO1999062517A1 (pt) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
US20050032841A1 (en) * | 1999-04-20 | 2005-02-10 | Steven Walkley | Therapeutic compositions and methods of treating glycolipid storage related disorders |
DE60138535D1 (de) * | 2000-02-04 | 2009-06-10 | Children S Hospital Res Founda | Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten |
EP2204360A1 (en) * | 2001-09-07 | 2010-07-07 | Seikagaku Corporation | Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient |
US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
AU2003281195A1 (en) * | 2002-07-05 | 2004-01-23 | Roderick Frederick Gerardus Joseph King | Aqueous formulation comprising digestible saccharides to reduce the tendency to cardiovascular disease in a subject |
AU2003284886A1 (en) * | 2002-10-21 | 2004-05-13 | William E. Balch | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE |
EP2332567B1 (en) * | 2003-01-31 | 2015-04-08 | The Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
US7446098B2 (en) * | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
EP1633356A1 (en) * | 2003-05-22 | 2006-03-15 | The Hospital for Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
EP1682504B1 (en) * | 2003-11-12 | 2012-12-26 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US7488721B2 (en) * | 2004-05-13 | 2009-02-10 | Mcmaster University | Real time methylumbelliferone-based assay |
US20090239807A1 (en) * | 2004-05-24 | 2009-09-24 | Mia Horowitz | Methods and kits for diagnosing and/or assessing severity and treating gaucher disease |
JP2008503590A (ja) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | 組成物を細胞にデリバリーするための医学用システム及び方法 |
US8889127B2 (en) * | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
FR2873377B1 (fr) * | 2004-07-23 | 2006-10-13 | Sanofi Synthelabo | Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation |
KR20080025373A (ko) * | 2005-05-17 | 2008-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법 |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
ES2485369T3 (es) * | 2005-06-08 | 2014-08-13 | Amicus Therapeutics, Inc. | Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas |
FR2887549B1 (fr) * | 2005-06-23 | 2009-07-10 | Centre Nat Rech Scient | Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation |
US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
AU2015230773B2 (en) * | 2006-05-16 | 2017-09-28 | Amicus Therapeutics Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
US7851143B2 (en) * | 2006-05-16 | 2010-12-14 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Fabry disease |
AU2013205532B8 (en) * | 2006-05-16 | 2015-07-16 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
ES2364586T3 (es) * | 2006-05-24 | 2011-09-07 | Amicus Therapeutics, Inc. | Sal tartrato de isofagomina y métodos de uso. |
WO2007140212A2 (en) * | 2006-05-24 | 2007-12-06 | Amicus Therapeutics, Inc. | Tartrate salt of isofagomine and methods of use |
BRPI0713442A2 (pt) * | 2006-06-23 | 2012-03-06 | Amicus Therapeutics, Inc. | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
WO2008088581A2 (en) * | 2006-08-02 | 2008-07-24 | United Therapeutics Corporation | Liposome treatment of viral infections |
WO2008075957A1 (en) * | 2006-12-21 | 2008-06-26 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
EP2155197A4 (en) * | 2007-03-09 | 2011-10-12 | Link Medicine Corp | TREATMENT OF LYSOSOMAL STORAGE DISEASES |
WO2008121826A2 (en) * | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
CA2684042A1 (en) * | 2007-04-13 | 2008-10-23 | Amicus Therapeutics Inc. | Use of substrates as pharmacological chaperones |
US8399525B2 (en) * | 2007-04-13 | 2013-03-19 | Amicus Therapeutics, Inc. | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
US9056101B2 (en) * | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
AU2008254594B2 (en) | 2007-05-22 | 2013-06-27 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
WO2009049422A1 (en) * | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease |
US20100317690A1 (en) * | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
EP3470077B1 (en) * | 2008-02-12 | 2020-08-26 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
CN102046151A (zh) * | 2008-03-26 | 2011-05-04 | 牛津大学 | 靶向内质网的脂质体 |
EP2484371B1 (en) | 2008-06-26 | 2014-12-17 | Orphazyme APS | Use of Hsp70 as a regulator of enzymatic activity |
WO2010048532A1 (en) * | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
US20100119502A1 (en) * | 2008-11-11 | 2010-05-13 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
CN102427804A (zh) * | 2009-03-27 | 2012-04-25 | 牛津大学之校长及学者 | 降低胆固醇水平的脂质体 |
GB0906159D0 (en) * | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
US20110070643A1 (en) * | 2009-05-26 | 2011-03-24 | Do Hung V | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics |
US9206457B2 (en) * | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
US20110112041A1 (en) * | 2009-10-01 | 2011-05-12 | Baylor Research Institute | Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease |
PT2995306T (pt) * | 2009-10-19 | 2019-03-29 | Amicus Therapeutics Inc | Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal |
PT2490532T (pt) | 2009-10-19 | 2017-02-23 | Amicus Therapeutics Inc | Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central |
EP2490712B1 (en) | 2009-10-19 | 2015-07-08 | Amicus Therapeutics, Inc. | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
CA2788175A1 (en) * | 2010-01-28 | 2011-08-04 | Raptor Discoveries Inc. | Method for treating liver disorders with receptor associated protein (rap) peptide-fucosidase inhibitor conjugates |
CA2788983A1 (en) * | 2010-02-02 | 2011-08-11 | The Chancellor, Masters And Scholars Of The University Of Oxford | Synthesis of dgjnac from d-glucuronolactone and use to inhibit alpha-n-acetylgalactosaminidases |
CA2817773A1 (en) | 2010-11-30 | 2012-06-07 | Orphazyme Aps | Methods for increasing intracellular activity of hsp70 |
WO2012125402A2 (en) * | 2011-03-11 | 2012-09-20 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
ES2639832T3 (es) | 2011-11-29 | 2017-10-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos y composiciones farmacéuticas para el tratamiento de la enfermedad de Darier |
JP6236406B2 (ja) | 2012-03-07 | 2017-11-22 | アミカス セラピューティックス インコーポレイテッド | ポンペ病の処置のための高濃度α−グルコシダーゼ組成物 |
ES2786128T3 (es) | 2012-06-01 | 2020-10-08 | Icahn School Med Mount Sinai | Niveles de ceramida en el tratamiento y prevención de infecciones |
CA2897432A1 (en) | 2013-01-09 | 2014-07-17 | Amicus Therapeutics, Inc. | Stable parenteral dnj compositions |
MX2015012471A (es) | 2013-03-14 | 2016-08-03 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas. |
US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
CA2961097C (en) | 2014-09-15 | 2023-09-26 | Orphazyme Aps | Extended-release pharmaceutical formulation comprising arimoclomol |
CR20170107A (es) | 2014-09-30 | 2017-09-01 | Amicus Therapeutics Inc | Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados |
CN107205818B (zh) | 2015-02-05 | 2019-05-10 | 卡迪尔维尔福股份有限公司 | 带有轴向滑动框架的人工瓣膜 |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
EA201891507A1 (ru) | 2015-12-30 | 2018-12-28 | Амикус Терапьютикс, Инк. | Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе |
CN109069494A (zh) * | 2016-03-22 | 2018-12-21 | 阿米库斯治疗学公司 | 治疗在gla基因中具有g9331a突变的患者的法布里病的方法 |
MX2018011951A (es) | 2016-03-30 | 2019-02-13 | Amicus Therapeutics Inc | Metodo para seleccionar proteinas recombinantes ricas en m6p. |
BR112018069965A2 (pt) | 2016-03-30 | 2019-01-29 | Amicus Therapeutics Inc | formulações compreendendo alfa-glucosidase ácida recombinante |
WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
LT3448382T (lt) | 2016-04-29 | 2021-04-12 | Orphazyme A/S | Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti |
AR109103A1 (es) | 2016-07-19 | 2018-10-31 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
FI3630114T3 (fi) | 2017-05-30 | 2024-01-30 | Amicus Therapeutics Inc | Migalastaatti fabry-potilaiden hoitamiseksi, joilla on heikentynyt munuaistoiminta |
US10251873B2 (en) | 2017-05-30 | 2019-04-09 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
UA125938C2 (uk) | 2017-06-01 | 2022-07-13 | Ідорсія Фармасьютікалз Лтд | Кристалічна форма n-бутилдеоксигалактоноджириміцину |
JP7066157B2 (ja) * | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | ファブリー病治療用医薬の組合せ物及びその利用 |
SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
JP2020531550A (ja) | 2017-08-28 | 2020-11-05 | アミカス セラピューティックス インコーポレイテッド | ファブリー病患者における心臓機能の強化及び/または安定化方法 |
US20200206323A1 (en) * | 2017-09-08 | 2020-07-02 | The Nemours Foundation | An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases |
US10856972B2 (en) | 2017-09-19 | 2020-12-08 | Cardiovalve Ltd. | Prosthetic valve with angularly offset atrial anchoring arms and ventricular anchoring legs |
CN107699590A (zh) * | 2017-10-13 | 2018-02-16 | 成都中医药大学 | 一种制备重组人α‑L‑艾杜糖醛酸酶的方法 |
ES2716305B2 (es) | 2017-12-11 | 2019-11-27 | Fund Biomedica Galicia Sur | Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal |
WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
EP4316589A3 (en) | 2018-02-06 | 2024-04-24 | Amicus Therapeutics, Inc. | Treatment of patients with classic fabry disease |
WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
EA202190569A1 (ru) | 2018-08-20 | 2021-06-01 | Амикус Терапьютикс, Инк. | Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla |
TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
EA202290024A1 (ru) | 2019-06-11 | 2022-03-14 | Амикус Терапьютикс, Инк. | Способы лечения болезни фабри у пациентов с почечной недостаточностью |
CA3147055A1 (en) | 2019-08-07 | 2021-02-11 | Elfrida Benjamin | Methods of treating fabry disease in patients having a mutation in the gla gene |
WO2021067324A1 (en) | 2019-10-04 | 2021-04-08 | Academia Sinica | Methods of treating pompe disease |
KR20220134522A (ko) * | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
KR20220150902A (ko) * | 2020-02-10 | 2022-11-11 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 파브리 질병을 치료하는 방법 |
JP2023516753A (ja) | 2020-03-06 | 2023-04-20 | アミカス セラピューティックス インコーポレイテッド | Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 |
NZ800483A (en) | 2020-11-19 | 2024-03-22 | Zevra Denmark As | Processes for preparing arimoclomol citrate and intermediates thereof |
US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
EP4370120A1 (en) | 2021-07-12 | 2024-05-22 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in pediatric patients |
WO2023060233A1 (en) | 2021-10-08 | 2023-04-13 | Amicus Therapeutics, Inc. | Biomarkers for lysosomal storage diseases |
US20240197706A1 (en) | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
JPS61280472A (ja) | 1985-06-05 | 1986-12-11 | Shionogi & Co Ltd | β−ガラクトシダ−ゼ阻害物質ガラクトスタチン類およびその製造方法 |
WO1987003903A1 (en) | 1985-12-23 | 1987-07-02 | Fred Hutchinson Cancer Research Center | Regulating retroviral replication, infection, and pathogenesis |
DE3737523A1 (de) | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
US5192772A (en) | 1987-12-09 | 1993-03-09 | Nippon Shinyaku Co. Ltd. | Therapeutic agents |
US5250545A (en) | 1988-02-12 | 1993-10-05 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitor methods |
FR2640621B1 (fr) | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
US5043273A (en) | 1989-08-17 | 1991-08-27 | Monsanto Company | Phosphorylated glycosidase inhibitor prodrugs |
US5030638A (en) | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
US5504078A (en) | 1990-06-08 | 1996-04-02 | Merrell Dow Pharmaceuticals Inc. | α-glucosidase inhibitors |
EP0536402A4 (en) | 1990-06-29 | 1993-05-12 | Nippon Shinyaku Company, Limited | Piperidine derivative |
US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
US5399567A (en) * | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
JPH0748398A (ja) | 1993-08-03 | 1995-02-21 | Nippon Oil Co Ltd | 変性蛋白質の再生方法及び変性蛋白質再生剤 |
US5691306A (en) | 1993-08-26 | 1997-11-25 | National Research Council Of Canada | Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production |
EP0739205B1 (en) | 1994-01-13 | 1999-11-24 | G.D. Searle & Co. | Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections |
AU1876095A (en) | 1994-02-25 | 1995-09-11 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
US6177447B1 (en) | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
NZ334721A (en) | 1996-09-13 | 2001-01-26 | Transkaryotic Therapies Inc | Purified human alpha-galactosidase A and therapeutic use |
GB9700233D0 (en) | 1997-01-08 | 1997-02-26 | Univ London | Use of glycosidase inhibitors |
US6210666B1 (en) * | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
MY122499A (en) | 1997-11-10 | 2006-04-29 | Searle & Co | Use of alkylated iminosugars to treat multidrug resistance |
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
AU2590099A (en) | 1998-02-09 | 1999-08-23 | William J. Netzer | Protein folding inhibitors |
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
AU1734600A (en) | 1998-11-17 | 2000-06-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Identification of glycosphingolipids that promote hiv-1 entry into cells |
EA003326B1 (ru) | 1998-12-02 | 2003-04-24 | Пфайзер Продактс Инк. | Способ лечения рака |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
JP2000219632A (ja) | 1999-01-28 | 2000-08-08 | Toyotama Koryo Kk | カロリー軽減剤 |
WO2000056334A1 (en) | 1999-03-19 | 2000-09-28 | The Trustees Of Boston College | Use of imino sugars for anti-tumor therapy |
CA2306039A1 (en) | 1999-04-19 | 2000-10-19 | Schering Corporation | Hcv combination therapy |
GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
US6476194B1 (en) | 1999-06-29 | 2002-11-05 | National Research Council Of Canada | Method for folding unfolded proteins |
CA2378776A1 (en) | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
JP2003506406A (ja) | 1999-08-10 | 2003-02-18 | ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード | 長鎖n−アルキル化合物およびそのオキサ誘導体 |
WO2001021652A1 (en) | 1999-09-24 | 2001-03-29 | The Johns Hopkins University School Of Medicine | Methods for identifying an agent that corrects defective protein folding |
EP1250129A2 (en) | 2000-01-20 | 2002-10-23 | Washington University | METHODS TO TREAT $g(a)-1-ANTITRYPSIN DEFICIENCY |
AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
WO2002028348A2 (en) | 2000-10-04 | 2002-04-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
JP2002190202A (ja) | 2000-10-12 | 2002-07-05 | Koito Mfg Co Ltd | ヘッドランプ |
JP3589449B2 (ja) | 2001-02-26 | 2004-11-17 | 株式会社ユニレック | 静電容量センサ、管内流動判断装置、管内流動制御装置 |
JP4802548B2 (ja) * | 2005-04-28 | 2011-10-26 | シンフォニアテクノロジー株式会社 | Icチップ実装体の製造装置 |
US7174582B1 (en) * | 2005-08-17 | 2007-02-13 | Kevin J Leary | Crib mattress bouncer |
WO2009102997A2 (en) | 2008-02-14 | 2009-08-20 | Signum Biosciences, Inc. | Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase |
DK2362866T3 (en) | 2008-11-11 | 2015-10-12 | Signum Biosciences Inc | Isoprenylforbindelser and their methods |
EP2389357A4 (en) | 2009-01-20 | 2013-01-23 | Signum Biosciences Inc | INFLAMMATORY COMPLEXES |
-
1998
- 1998-06-01 US US09/087,804 patent/US6274597B1/en not_active Expired - Lifetime
-
1999
- 1999-05-28 JP JP2000551773A patent/JP4602548B2/ja not_active Expired - Lifetime
- 1999-05-28 ES ES99925611T patent/ES2333561T3/es not_active Expired - Lifetime
- 1999-05-28 EP EP99925611A patent/EP1083899B1/en not_active Expired - Lifetime
- 1999-05-28 DK DK99925611.8T patent/DK1083899T3/da active
- 1999-05-28 PT PT90117615T patent/PT2143420E/pt unknown
- 1999-05-28 DK DK09011761.5T patent/DK2143420T3/da active
- 1999-05-28 EP EP09011761.5A patent/EP2143420B1/en not_active Expired - Lifetime
- 1999-05-28 PT PT99925611T patent/PT1083899E/pt unknown
- 1999-05-28 AT AT99925611T patent/ATE442851T1/de active
- 1999-05-28 ES ES09011761.5T patent/ES2507515T3/es not_active Expired - Lifetime
- 1999-05-28 DE DE69941429T patent/DE69941429D1/de not_active Expired - Lifetime
- 1999-05-28 CA CA2333965A patent/CA2333965C/en not_active Expired - Lifetime
- 1999-05-28 AU AU41861/99A patent/AU4186199A/en not_active Abandoned
- 1999-05-28 WO PCT/US1999/010479 patent/WO1999062517A1/en active Application Filing
-
2000
- 2000-06-26 US US09/604,053 patent/US6583158B1/en not_active Expired - Lifetime
-
2001
- 2001-08-10 US US09/927,285 patent/US6774135B2/en not_active Expired - Lifetime
- 2001-09-07 US US09/948,348 patent/US6599919B2/en not_active Expired - Lifetime
-
2002
- 2002-06-14 US US10/172,604 patent/US6589964B2/en not_active Expired - Lifetime
- 2002-11-26 US US10/304,395 patent/US6916829B2/en not_active Expired - Lifetime
-
2004
- 2004-06-14 US US10/868,133 patent/US7622485B2/en not_active Expired - Fee Related
- 2004-11-16 US US10/989,258 patent/US7141582B2/en not_active Expired - Lifetime
-
2005
- 2005-10-31 US US11/264,672 patent/US7514453B2/en not_active Expired - Fee Related
-
2006
- 2006-09-27 US US11/528,903 patent/US7812033B2/en not_active Expired - Fee Related
-
2009
- 2009-11-23 US US12/624,026 patent/US8633221B2/en not_active Expired - Fee Related
- 2009-12-16 CY CY20091101305T patent/CY1112845T1/el unknown
-
2010
- 2010-08-02 JP JP2010173733A patent/JP5528941B2/ja not_active Expired - Lifetime
- 2010-09-24 US US12/890,014 patent/US8436018B2/en not_active Expired - Fee Related
-
2013
- 2013-04-22 US US13/867,914 patent/US8841322B2/en not_active Expired - Fee Related
- 2013-12-20 US US14/136,418 patent/US9265780B2/en not_active Expired - Fee Related
-
2014
- 2014-08-18 US US14/461,827 patent/US20150258129A1/en not_active Abandoned
- 2014-09-24 CY CY20141100776T patent/CY1115583T1/el unknown
-
2016
- 2016-01-25 US US15/005,371 patent/US20160346262A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1083899E (pt) | Derivados de 1-desoxi-galactonojirimicina e respectiva utilização no tratamento de doenças de acumulação lisossomal, por intensificação da alfa-galactosidase a lisossomal | |
AU576365B2 (en) | Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas | |
MX9603479A (es) | Derivados de 4-amino de acido micofenolico con actividad inmunosupresora. | |
AU6950387A (en) | Light array assembly for photoactivation patient treatment system | |
IL135578A0 (en) | Compositions and methods for treating lysosomal storage disease | |
EP1820862A3 (en) | Medical preparations for the treatment of alpha-galactosidase a deficiency | |
AU5278590A (en) | Animal model for benign prostatic disease | |
HK1012634A1 (en) | 6-substituted mycophenolic and derivatives with immunosuppressive activity | |
EP0983062A4 (en) | METHOD FOR INCREASING THE CONCENTRATION OF ASCOBIC ACID IN PERSONAL BRAIN TISSUE | |
AU8091787A (en) | The use of paroxetine to treat pain | |
IL91703A0 (en) | Animal model for diagnosing therapeutic agents against aids | |
WO1994006449A3 (en) | Morphogen-induced liver regeneration | |
SE8701004D0 (sv) | Method for therapy of leukemias and certain other malignancies | |
MY103210A (en) | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds. | |
AU591046B2 (en) | Physiologically active agent for agricultural use | |
HUP9802146A3 (en) | Process for preparing optically active 2-amino-omega-oxoalkanoic acid derivatives and the compounds | |
AU5277000A (en) | Stimulating transport of glucose into animal tissue by the administration of pinitol | |
EP1153928A4 (en) | 2-METHYL-3-BUTENYL-1-PYROPHOSPHORIC ACIDS AND MEANS FOR THE TREATMENT OF LYMPHOCYTES | |
AU1621788A (en) | Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease | |
WO1998036778A8 (en) | Sustained drug delivery and compositions useful therefor | |
IE810311L (en) | Guanylamidines. | |
AU6950487A (en) | Irradiation chamber for photoactivation patient treatment system | |
YU58900A (sh) | Lečenje paničnih napada | |
IE880515L (en) | Therapeutic agent comprising a phthalazine derivative | |
AU1162788A (en) | Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases |